Toremifene-d6

• Description:

  Toremifene-d6 is deuterium labeled Toremifene. Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 μM and 2.6 μM, respectively[1][2].

• Product Name Alternative:

  Z-Toremifene-d6; NK 622-d6 (free base) ; FC-1157a-d6 (free base)

• UNSPSC:

  12352005

• Target:

  Estrogen Receptor/ERR; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Others; Vitamin D Related/Nuclear Receptor

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H]C(N(C([2H])([2H])[2H])CCOC1=CC=C(/C(C2=CC=CC=C2)=C(C3=CC=CC=C3)/CCCl)C=C1)([2H])[2H]

• Molecular Formula:

  C26H22D6ClNO

• Molecular Weight:

  412.00

• References & Citations:

  [2]Gauri J Sabnis, Luciana Macedo, Olga Goloubeva, Toremifene - Atamestane; Alone or In Combination: Predictions from the Preclinical Intratumoral Aromatase Model. J Steroid Biochem Mol Biol. 2008 January; 108 (1-2) : 1-7.|[3]Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4.|[4]Matthew R Smith, Selective Estrogen Receptor Modulators to Prevent Treatment-Related Osteoporosis.Rev Urol. 2005; 7 (Suppl 3) : S30-S35.|[5]Taneja SS, Morton R, Barnette G, Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol. 2013 Feb 10;31 (5) :523-9.|[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported